BRAINSTORM CELL THERAPEUTICS INC.
Close on Oct 19, 2026
- Market cap
- $8.50M
- P/E (TTM)
- –
- Dividend yield
- –
About Brainstorm Cell Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing autologous cellular therapies for neurodegenerative conditions. Its core technology platform, NurOwn, processes a patient's own bone marrow-derived mesenchymal stem cells to produce neurotrophic factors that promote nerve cell survival and reduce neuroinflammation. The company primarily directs its investigational therapies toward neurodegenerative diseases such as amyotrophic lateral sclerosis, progressive multiple sclerosis, and Alzheimer's disease. Its treatments target patients suffering from these central nervous system disorders.
The business conducts operations across the United States and Israel, employing 20 workers. Its research and development center operates in Petach Tikva, Israel, whereas most of the senior leadership team resides in the United States. Additionally, the company's late-phase clinical trial facilities for amyotrophic lateral sclerosis and progressive multiple sclerosis are situated entirely within the United States. While the text details these geographic operational facilities, it does not explicitly designate a formal headquarters address.
Summary of the business section of Brainstorm Cell Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BRAINSTORM CELL THERAPEUTICS INC.
- Headquarters
- New York, NY
- Address
- 1325 Avenue Of Americas, 28th Floor 10019
- Phone
- (201) 488-0460
- Website
- brainstorm-cell.com
- Employees
- 20, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- BCLI
- Exchange
- OTC
- Shares outstanding
- 11M, Aug 11, 2026
- Public float
- $10.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Oct 1, 2024; 1-for-15 reverse, Sep 30, 2024; 1-for-15 reverse, Nov 13, 2014; 1-for-15 reverse, Sep 16, 2014
- SEC CIK
- 1137883
- CUSIP
- 10501E300
- ISIN
- US10501E3009
- LEI
- 529900ULKWCLO3ZHXL41
- EIN
- 20-7273918
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Peter Joe Pitts | Executive Chairman, Director | – |
| Uri Yablonka | EVP & Chief Business Officer, Director | 218,464 |
| Alla Patlis | See Remarks | 144,349 |
| Chaim Lebovits | President & CEO | 2,134,349 |
| Jacob A. Frenkel | Director | 343,777 |
| Irit Arbel | Director | 161,054 |
| Ibrahim B. Dagher | Director | 79,515 |
| Nir Naor | Director | 31,465 |
| Anthony J. Polverino | Director | 25,730 |
| Menghisteab Bairu | Director | 24,000 |
| Hartoun Hartounian | Director | 52,000 |
| Stacy Lindborg | Director | 48,229 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Mr Chaim Lebovits | $750.30K | $694.25K | $382.36K | $4 | – |
| FY2024 Stacy Lindborg | $346.38K | $301.07K | $382.36K | $4 | – |
| FY2023 Mr Chaim Lebovits | $1.13M | $822.88K | $409.01K | $7 | – |
| FY2023 Stacy Lindborg | $1.01M | $724.56K | $409.01K | $7 | – |
| FY2022 Mr Chaim Lebovits | $1.12M | $897.25K | $832.05K | $41 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We currently employ 20 employees in the United States and in Israel.”
Corporate history
Events identified from SEC filings